195 related articles for article (PubMed ID: 33760395)
1. Regulation of Monocyte Adhesion and Type I Interferon Signaling by CD52 in Patients With Systemic Sclerosis.
Rudnik M; Rolski F; Jordan S; Mertelj T; Stellato M; Distler O; Blyszczuk P; Kania G
Arthritis Rheumatol; 2021 Sep; 73(9):1720-1730. PubMed ID: 33760395
[TBL] [Abstract][Full Text] [Related]
2. A macrophage marker, Siglec-1, is increased on circulating monocytes in patients with systemic sclerosis and induced by type I interferons and toll-like receptor agonists.
York MR; Nagai T; Mangini AJ; Lemaire R; van Seventer JM; Lafyatis R
Arthritis Rheum; 2007 Mar; 56(3):1010-20. PubMed ID: 17328080
[TBL] [Abstract][Full Text] [Related]
3. Interferon and alternative activation of monocyte/macrophages in systemic sclerosis-associated pulmonary arterial hypertension.
Christmann RB; Hayes E; Pendergrass S; Padilla C; Farina G; Affandi AJ; Whitfield ML; Farber HW; Lafyatis R
Arthritis Rheum; 2011 Jun; 63(6):1718-28. PubMed ID: 21425123
[TBL] [Abstract][Full Text] [Related]
4. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis.
Brkic Z; van Bon L; Cossu M; van Helden-Meeuwsen CG; Vonk MC; Knaapen H; van den Berg W; Dalm VA; Van Daele PL; Severino A; Maria NI; Guillen S; Dik WA; Beretta L; Versnel MA; Radstake T
Ann Rheum Dis; 2016 Aug; 75(8):1567-73. PubMed ID: 26371289
[TBL] [Abstract][Full Text] [Related]
5. The Long Non-coding RNA NRIR Drives IFN-Response in Monocytes: Implication for Systemic Sclerosis.
Mariotti B; Servaas NH; Rossato M; Tamassia N; Cassatella MA; Cossu M; Beretta L; van der Kroef M; Radstake TRDJ; Bazzoni F
Front Immunol; 2019; 10():100. PubMed ID: 30804934
[TBL] [Abstract][Full Text] [Related]
6. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis.
Chizzolini C; Raschi E; Rezzonico R; Testoni C; Mallone R; Gabrielli A; Facchini A; Del Papa N; Borghi MO; Dayer JM; Meroni PL
Arthritis Rheum; 2002 Jun; 46(6):1602-13. PubMed ID: 12115192
[TBL] [Abstract][Full Text] [Related]
7. Histone modifications underlie monocyte dysregulation in patients with systemic sclerosis, underlining the treatment potential of epigenetic targeting.
van der Kroef M; Castellucci M; Mokry M; Cossu M; Garonzi M; Bossini-Castillo LM; Chouri E; Wichers CGK; Beretta L; Trombetta E; Silva-Cardoso S; Vazirpanah N; Carvalheiro T; Angiolilli C; Bekker CPJ; Affandi AJ; Reedquist KA; Bonte-Mineur F; Zirkzee EJM; Bazzoni F; Radstake TRDJ; Rossato M
Ann Rheum Dis; 2019 Apr; 78(4):529-538. PubMed ID: 30793699
[TBL] [Abstract][Full Text] [Related]
8. Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop.
Masuda A; Yasuoka H; Satoh T; Okazaki Y; Yamaguchi Y; Kuwana M
Arthritis Res Ther; 2013 Jul; 15(4):R74. PubMed ID: 23845159
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes.
Farina A; Peruzzi G; Lacconi V; Lenna S; Quarta S; Rosato E; Vestri AR; York M; Dreyfus DH; Faggioni A; Morrone S; Trojanowska M; Farina GA
Arthritis Res Ther; 2017 Feb; 19(1):39. PubMed ID: 28245863
[TBL] [Abstract][Full Text] [Related]
10. Immune complexes containing scleroderma-specific autoantibodies induce a profibrotic and proinflammatory phenotype in skin fibroblasts.
Raschi E; Chighizola CB; Cesana L; Privitera D; Ingegnoli F; Mastaglio C; Meroni PL; Borghi MO
Arthritis Res Ther; 2018 Aug; 20(1):187. PubMed ID: 30157947
[TBL] [Abstract][Full Text] [Related]
11. Increased frequencies of circulating CXCL10-, CXCL8- and CCL4-producing monocytes and Siglec-3-expressing myeloid dendritic cells in systemic sclerosis patients.
Carvalheiro T; Horta S; van Roon JAG; Santiago M; Salvador MJ; Trindade H; Radstake TRDJ; da Silva JAP; Paiva A
Inflamm Res; 2018 Feb; 67(2):169-177. PubMed ID: 29127442
[TBL] [Abstract][Full Text] [Related]
12. [Altered serum cytokine expression profile in systemic sclerosis and its regulatory mechanisms].
Zhu HL; DU Q; Chen WL; Zuo XX; Li QZ; Liu SJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Aug; 51(4):716-722. PubMed ID: 31420628
[TBL] [Abstract][Full Text] [Related]
13. Non-classical circulating monocytes expressing high levels of microsomal prostaglandin E2 synthase-1 tag an aberrant IFN-response in systemic sclerosis.
Villanueva-Martin G; Acosta-Herrera M; Carmona EG; Kerick M; Ortego-Centeno N; Callejas-Rubio JL; Mages N; Klages S; Börno S; Timmermann B; Bossini-Castillo L; Martin J
J Autoimmun; 2023 Nov; 140():103097. PubMed ID: 37633117
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Long Non-Coding RNAs in Systemic Sclerosis Monocytes: A Potential Role for PSMB8-AS1 in Altered Cytokine Secretion.
Servaas NH; Mariotti B; van der Kroef M; Wichers CGK; Pandit A; Bazzoni F; Radstake TRDJ; Rossato M
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922041
[TBL] [Abstract][Full Text] [Related]
15. Angiopoietin-2 Promotes Inflammatory Activation in Monocytes of Systemic Sclerosis Patients.
Carvalheiro T; Lopes AP; van der Kroef M; Malvar-Fernandez B; Rafael-Vidal C; Hinrichs AC; Servaas NH; Bonte-Mineur F; Kok MR; Beretta L; Zimmermann M; Marut W; Pego-Reigosa JM; Radstake TRDJ; Garcia S
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33333969
[TBL] [Abstract][Full Text] [Related]
16. Endothelial Response to Type I Interferon Contributes to Vasculopathy and Fibrosis and Predicts Disease Progression of Systemic Sclerosis.
Yin H; Distler O; Shen L; Xu X; Yuan Y; Li R; Liu B; Li Q; Huang Q; Xie F; Zhang Z; Liang R; Dai X; Chen X; Li B; Yan Q; Lu L
Arthritis Rheumatol; 2024 Jan; 76(1):78-91. PubMed ID: 37488975
[TBL] [Abstract][Full Text] [Related]
17. A cell type-specific transcriptomic approach to map B cell and monocyte type I interferon-linked pathogenic signatures in Multiple Sclerosis.
Severa M; Rizzo F; Srinivasan S; Di Dario M; Giacomini E; Buscarinu MC; Cruciani M; Etna MP; Sandini S; Mechelli R; Farina A; Trivedi P; Hertzog PJ; Salvetti M; Farina C; Coccia EM
J Autoimmun; 2019 Jul; 101():1-16. PubMed ID: 31047767
[TBL] [Abstract][Full Text] [Related]
18. A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement.
Trombetta AC; Soldano S; Contini P; Tomatis V; Ruaro B; Paolino S; Brizzolara R; Montagna P; Sulli A; Pizzorni C; Smith V; Cutolo M
Respir Res; 2018 Sep; 19(1):186. PubMed ID: 30249259
[TBL] [Abstract][Full Text] [Related]
19. Flow cytometry evaluation of CD14/CD16 monocyte subpopulations in systemic sclerosis patients: a cross sectional controlled study.
Schneider L; Marcondes NA; Hax V; da Silva Moreira IF; Ueda CY; Piovesan RR; Xavier R; Chakr R
Adv Rheumatol; 2021 May; 61(1):27. PubMed ID: 34022965
[TBL] [Abstract][Full Text] [Related]
20. T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review.
Almeida I; Silva SV; Fonseca AR; Silva I; Vasconcelos C; Lima M
Clin Rev Allergy Immunol; 2015 Dec; 49(3):347-69. PubMed ID: 26445774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
